KRAS and neoplasm: Using a LSL:KrasG12D/+; Lkb1flox/flox (LSL=Lox-stop-Lox) mouse model of lung cancer, we demonstrated previously that Lkb1 inactivation dramatically accelerated KRAS-driven lung cancer progression and changed the tumour spectrum from purely ADC to ADC and SCC26.